Global Male Hypogonadism Market Size and Forecast 2024-2033|Allergan PLC, Pfizer Inc., Bayer AG, Eli Lilly and Company Ltd., Endo International plc

The Male Hypogonadism  by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Male Hypogonadism  Market:

https://www.thebusinessresearchcompany.com/report/male-hypogonadism-global-market-report

According to The Business Research Company’s Male Hypogonadism , The male hypogonadism market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.8 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%.  The  growth in the historic period can be attributed to aging population, awareness and diagnosis, lifestyle factors, chronic illnesses, treatment seeking behavior.

The male hypogonadism market size is expected to see strong growth in the next few years. It will grow to $4.77 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%.  The growth in the forecast period can be attributed to rising awareness, prevalence of lifestyle-related conditions, innovations in therapies, emphasis on men’s health, telemedicine and healthcare accessibility.. Major trends in the forecast period include attention to psychological and sexual health, exploration of nutraceuticals and lifestyle interventions, market expansion in emerging economies, collaborative research initiatives, focus on long-term safety and monitoring.

The increase in infertility rates is expected to propel the growth of the male hypogonadism market going forward. Infertility refers to a condition affecting the male or female reproductive system that is characterized by the inability to conceive after 12 months or longer of frequent, unprotected sexual activity. Male hypogonadism, which can lead to decreased sperm production and infertility, is one of the potential causes of male infertility. As a result, the increasing prevalence of male infertility is expected to drive the growth of the male hypogonadism market. For instance, in March 2023, according to the National Institutes of Health (NIH), a US-based Department of Health and Human Services in North America, the estimated male infertility rate is between 4.5% – 6%, while it’s 9% in Australia and could be as high as 8% to 12% in Eastern Europe.  Also, according to a 2021 study published by the Libyan Journal of Medical Sciences, around 70% of infertility is attributed to male factors in Libya. Therefore, an increase in the infertility rate is driving the growth of the male hypogonadism market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9969&type=smp

The male hypogonadism  market covered in this report is segmented –

1) By Type: Klinefelters Syndrome, Kallmann Syndrome, Pituitary Disorders, Other Types

2) By Drug Delivery: Topical Gels, Injectables, Transdermal Patches, Other Drug Deliveries

3) By Therapy: Testosterone Therapy, Gonadotropin-Releasing Hormone Therapy

Product innovations are a key trend gaining popularity in the male hypogonadism market. Companies operating in the male hypogonadism market are innovating new products to sustain their position in the market. For instance, in June 2022, Halozyme, a US-based biotechnology company, launched Tlando, an oral treatment for testosterone replacement therapy of male hypogonadism. Tlando is a prescription drug that contains testosterone, and it is the first oral testosterone treatment approved by FDA. It is used to treat adult men who, as a result of certain medical disorders, have low or no testosterone.

The male hypogonadism  market report table of contents includes:

1. Executive Summary

2. Male Hypogonadism Market Characteristics

3. Male Hypogonadism Market Trends And Strategies

4. Male Hypogonadism Market – Macro Economic Scenario

5. Global Male Hypogonadism Market Size and Growth

.

.

.

26. South America Male Hypogonadism Market

27. Brazil Male Hypogonadism Market

28. Middle East Male Hypogonadism Market

29. Africa Male Hypogonadism Market

30. Male Hypogonadism Market Competitive Landscape And Company Profiles

Top Major Players:

  • Allergan PLC
  • Pfizer Inc
  • Bayer AG
  • Eli Lilly and Company Ltd
  • Endo International plc

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model